Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062145 | 1.00 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL14062374 | 1.00 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL14061971 | 0.90 | DGAT1 (0.82) | DGAT1 | |
| SCHEMBL14061873 | 0.89 | DGAT1 (0.84) | DGAT1 | |
| SCHEMBL14137214 | 0.89 | DGAT1 (0.84) | DGAT1 | |
| SCHEMBL17211844 | 0.89 | DGAT1 (0.80) | DGAT1 | |
| SCHEMBL17200583 | 0.89 | DGAT1 (0.80) | DGAT1 | |
| SCHEMBL15689345 | 0.86 | DGAT1 (0.75) | DGAT1 | |
| SCHEMBL17200606 | 0.84 | DGAT1 (0.72) | DGAT1 | |
| SCHEMBL17200555 | 0.84 | DGAT1 (0.72) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120154718-A | Functional hydrogel loaded with diacylglycerol acyltransferase inhibitor as well as preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2025-06-17 | — | — | CN | claimed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| CN-120154718-A | Functional hydrogel loaded with diacylglycerol acyltransferase inhibitor as well as preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2025-06-17 | — | — | CN | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-05-02 | — | — | US | disclosed |
| WO-2023242845-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | STAMBP, HSPBP1, ECPAS | DGAT1 4259/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | DGAT1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.